BioSpace News Archive

John R. Beaver Promoted to Executive Vice President and Chief Financial Officer

Dr. Preston joins experienced investment team to identify and invest in biopharmaceutical companies

Five New Board Members Added in Last 18 Months

Company Initiative Recognizes Community Health Centers for Crucial Role They Play in Safeguarding Public Health

Catabasis Pharmaceuticals, Inc. announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference on Wednesday, August 15, 2018 at 2:30pm ET at the Le Parker Meridien Hotel in New York, NY.

ACG Inspection (ACGI) has partnered with CertiRx Corporation, d.b.a. “Verinetics” for further enhancing its Traceability and Authenticity solutions in the Track and Trace industry.

Trial to Evaluate the Combination of Rubraca® (rucaparib) and OPDIVO® (nivolumab) in Patients with Advanced Ovarian Cancer.

PD-L1 IHC 22C3 pharmDx Can Now Be Used as an Aid to Identify Urothelial Carcinoma Patients for Treatment With KEYTRUDA® (pembrolizumab)

WellCare Health Plans, Inc. announced that on August 7, 2018 it priced an offering of 4,528,302 shares of its common stock at a public offering price of $265.00 per common share.

United Therapeutics Corporation announced that preliminary analysis indicates that the FREEDOM-EV clinical study of Orenitram® (treprostinil) extended-release tablets in patients suffering from pulmonary arterial hypertension (PAH) has met its primary endpoint of delayed time to first clinical worsening event.